Skip to main content Skip to section navigation Skip to footer
Top
Lantern Pharma Inc.
INVESTORS
Home
Investors
Contact
About
Welcome
Mission
Partnering
Patents
A.I. Platform
Our Technology
RADR®
Collaborations
Pipeline
Overview
LP100 | LP184 | LP284 | LP300 | ADC Program
Clinical Trials
Compassionate Use
Publications
Posters
TEAM
Leadership
Board of Directors
Advisors
Lantern Careers
MEDIA
News
Press
Social Media
Newsletter
Videos
Webinars
ContactInvestors

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • IR Calendar
    • Presentations
    • Media Coverage
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Board Diversity
  • News & Events

  • Overview
  • Press Releases
  • IR Calendar
  • Presentations
  • Media Coverage
  • Email Alerts
May 03, 2022 4:01pm EDT

Lantern Pharma Reports First Quarter 2022 Financial Results and Operational Highlights

Apr 26, 2022 7:15am EDT

Lantern Pharma's Board of Directors Names Maria Maccecchini, Ph.D. as a Director Nominee to Lantern's Board of Directors

Apr 22, 2022 7:00am EDT

Lantern Pharma to Report First Quarter 2022 Operating & Financial Results on May 3rd, 2022 at 4:30 p.m. ET

Mar 22, 2022 7:00am EDT

Lantern Pharma Announces Extension of Existing Share Repurchase Program

Mar 14, 2022 7:00am EDT

Lantern Pharma to Present Positive Preclinical Data on the Effectiveness of LP-184 in Brain Metastases at the American Association of Cancer Research (AACR) Annual Meeting

Mar 10, 2022 4:05pm EST

Lantern Pharma Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Operational Highlights

Mar 03, 2022 7:00am EST

Lantern Pharma Inc. to Report Fourth Quarter and Full Year 2021 Financial Results on March 10, 2022

Feb 15, 2022 6:59am EST

Lantern Pharma Expands into Additional Pediatric Cancers Through a Collaboration with The Greehey Children's Cancer Research Institute (GCCRI) at University of Texas Health Science Center-San Antonio

Jan 24, 2022 7:00am EST

Lantern Pharma Receives Rare Pediatric Disease and Orphan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of the Central Nervous System

Jan 18, 2022 6:30am EST

Lantern Pharma Announces Collaboration & Research Agreement with The Danish Cancer Society Research Center to Support Clinical Development of Drug Candidates, LP-100 and LP-184, in Solid Tumors

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 13
  • Next Pagearrow_forward
rss_feed News RSS
  • Email Alerts
  • Company Profile
  • Contacts
  • RSS News Feed

Join our Mailing List to get the latest Lantern news, sent right to your inbox

Sign me up for:

This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.
Never spam. Unsubscribe anytime.
Tweets by LanternPharma
View on Webflow
About
Welcome
Mission
Partnering
Patents
A.I. Platform
Our Technology
RADR®
Collaborations
Pipeline
Overview
LP100 | LP184 | LP284 | LP300 | ADC Program
Clinical Trials
Compassionate Use
Publications
Posters
TEAM
Leadership
Board Of Directors
Advisors
Lantern Careers
MEDIA
News
Press
Social Media
Newsletter
Videos
Webinars
Investors
Contact
TwitterYoutubeLinkedin
©Copyright 2023 Lantern Pharma Inc.
Privacy Policy